Top-line results from a Phase III clinical trial of BromSite (bromfenac + DuraSite delivery), from InSite Vision, for the reduction...
InSite Vision Incorporated has announced top-line results from its recently completed Phase III clinical trial of BromSite(ISV-303) for the reduction...
Sun Pharmaceutical Industries Ltd announced that one of its wholly owned subsidiaries has received approval from FDA for its New...
InSite Vision Inc, a company developing ophthalmic products for unmet eye care needs, announced that the FDA has accepted for...
Cardiff Oncology announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of PCM 075 (onvansertib) in KRAS-mutated metastatic colorectal cancer (mCRC) patients.
Sun Pharmaceutical Industries Ltd. has announced that one of its subsidiaries has entered into an agreement and plan of merger...
QLT Inc announced that it has entered into a merger agreement with InSite Vision Incorporated pursuant to which QLT will...